Skip to main content

Table 4 Prognostic factors for over all survival and TTF

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

 

Over all survival Time to treatment Failure

Stratification

Hazard ratio

p-value

95% C.I.

Hazard ratio

p-value

95% C.I.

Sex (male/female)

0.123

0.0128

0.024–0.640

0.225

0.0095

0.073–0.695

Age (69/<69)

0.634

0.6082

0.111–3.692

2.380

0.2269

0.583–9.713

ECOG PS (PS0/PS1/PS2)

0.016

0.0015

0.001–0.259

0.230

0.0007

0.001–0.152

Species of tumor (BDca/GBca)

0.095

0.0198

0.013–0.688

0.001

0.0411

0.0856–0.943

Disease status (locally advanced/postoperative recurrence)

0.121

0.0179

0.021–0.695

0.802

0.7388

0.001–0.152

Radiation (yes/no)

8.369

0.1491

0.467–150.112

0.603

0.4586

0.158–2.299

Previous chemotherapy (yes/no)

0.143

0.0255

0.016–1.241

0.495

0.4086

0.094–2.622

Initial CEA level (1 UL/<1 UL)

1.098

0.9053

0.234–5.160

2.453

0.1267

0.775–7.763

Interval decreasing CEA level (yes/no)

0.224

0.2859

0.014–3.499

1.734

0.5968

0.260–11.568

Initial CA19-9 level (5 UL/<5 UL)

0.078

0.0255

0.014–3.499

1.734

0.5968

0.260–11.568

Interval decreasing CA19-9 level(yes/no)

1.449

0.7667

0.125–16.774

0.326

0.2600

0.047–2.290

  1. (Cox proportional hazard model)
  2. Abbreveations
  3. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, CEA: carcinoembryonic antigen, UL: upper limit